No black box warning on record for Itvisma

As of the latest FDA labeling reviewed, Itvisma (ONASEMNOGENE ABEPARVOVEC-BRVE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Itvisma medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Prior to ITVISMA injection, assess liver function of patients by clinical examination and laboratory testing. Continue to monitor liver function for at least 3 months after injection, and at other times as clinically indicated. ( 2.1 , 2.4 , 5.1 ) Thrombocytopenia: Monitor platelet counts before ITVISMA injection, and at least weekly for the first month a

No black box warning on record for Itvisma

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Prior to ITVISMA injection, assess liver function of patients by clinical examination and laboratory testing. Continue to monitor liver function for at least 3 months after injection, and at other times as clinically indicated. ( 2.1 , 2.4 , 5.1 ) Thrombocytopenia: Monitor platelet counts before ITVISMA injection, and at least weekly for the first month a

Itvisma Black Box Warning

No black box warning on record for Itvisma

Other warnings & precautions

Itvisma Black Box Warning

No black box warning on record for Itvisma

Other warnings & precautions